- Home
- PAYS vs ATOS Comparison
PAYS vs ATOS Comparison
Compare PAYS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- ATOS
- Stock Information
- Founded
- PAYS 1995
- ATOS 2009
- Country
- PAYS United States
- ATOS United States
- Employees
- PAYS N/A
- ATOS N/A
- Industry
- PAYS Business Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- ATOS Health Care
- Exchange
- PAYS Nasdaq
- ATOS Nasdaq
- Market Cap
- PAYS 209.9M
- ATOS 174.8M
- IPO Year
- PAYS 1998
- ATOS 2012
- Fundamental
- Price
- PAYS $3.98
- ATOS $1.50
- Analyst Decision
- PAYS Strong Buy
- ATOS Strong Buy
- Analyst Count
- PAYS 3
- ATOS 3
- Target Price
- PAYS $6.17
- ATOS $6.25
- AVG Volume (30 Days)
- PAYS 147.3K
- ATOS 462.9K
- Earning Date
- PAYS 11-05-2024
- ATOS 11-19-2024
- Dividend Yield
- PAYS N/A
- ATOS N/A
- EPS Growth
- PAYS 368.11
- ATOS N/A
- EPS
- PAYS 0.14
- ATOS N/A
- Revenue
- PAYS $56,467,600.00
- ATOS N/A
- Revenue This Year
- PAYS $24.07
- ATOS N/A
- Revenue Next Year
- PAYS $14.42
- ATOS N/A
- P/E Ratio
- PAYS $28.59
- ATOS N/A
- Revenue Growth
- PAYS 27.75
- ATOS N/A
- 52 Week Low
- PAYS $2.20
- ATOS $0.62
- 52 Week High
- PAYS $5.59
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- PAYS 55.13
- ATOS 58.52
- Support Level
- PAYS $3.81
- ATOS $1.36
- Resistance Level
- PAYS $4.09
- ATOS $1.44
- Average True Range (ATR)
- PAYS 0.15
- ATOS 0.06
- MACD
- PAYS 0.05
- ATOS 0.01
- Stochastic Oscillator
- PAYS 80.36
- ATOS 96.77
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized, payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.